Click Here for 5% Off Your First Aladdin Purchase!

Ficlatuzumab (anti-HGF), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to HGF, >95%, high purity, Human IgG1, INHIBITOR of Hepatocyte growth factor inhibitor

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Application: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab170563
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab170563-100μg
100μg
In stock
$69.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Accession#:P14210 Gene ID:3082 HGF

Basic Description

Product NameFiclatuzumab (anti-HGF), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to HGF, >95%, high purity, Human IgG1
SynonymsDFNB39 antibody; F TCF antibody; Fibroblast derived tumor cytotoxic factor antibody; Hepatocyte growth factor (hepapoietin A; scatter factor) antibody; Hepatocyte growth factor antibody; Hepatocyte growth factor beta chain antibody; Hepatocyte growth fact
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityHGF
ApplicationELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of Hepatocyte growth factor inhibitor
Product Description

Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.

Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE27.6 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 178.7 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1174900-84-5

Images

Ficlatuzumab (anti-HGF) (Ab170563) - ELISA
Immobilized Recombinant human HGF protein (rp156180) at 1.0 μg/mL can bind Ficlatuzumab (anti-HGF) (Ab170563) with the EC₅₀ of 45.64 ng/mL.

Ficlatuzumab (anti-HGF) (Ab170563) - SEC
The purity of Ficlatuzumab (anti-HGF) (Ab170563) is more than 95% verified by HPLC.

Associated Targets

HGF Tchem Hepatocyte growth factor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0303072Certificate of AnalysisMar 08, 2024 Ab170563
ZJ24F0303071Certificate of AnalysisMar 08, 2024 Ab170563
ZJ24F0303070Certificate of AnalysisMar 08, 2024 Ab170563

Related Documents

References

1. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS..  (2008)  Design, synthesis, and biological evaluation of potent c-Met inhibitors..  J Med Chem,  51  (18): (5766-5779).  [PMID:18763753]
2. Liang Z, Ai J, Ding X, Peng X, Zhang D, Zhang R, Wang Y, Liu F, Zheng M, Jiang H, Liu H, Geng M, Luo C..  (2013)  Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway..  ACS Med Chem Lett,  (4): (408-413).  [PMID:24900685]
3. Hartmann, G G and 6 more authors..  (1992)  A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis..  Proceedings of the National Academy of Sciences of the United States of America,    (1):   [PMID:1280830]
4. Lokker, N A NA and 6 more authors..  (1992)  Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding..  The EMBO journal,      [PMID:1321034]
5. Shimizu, N N and 7 more authors..  (1992)  Hepatocyte growth factor is linked by O-glycosylated oligosaccharide on the alpha chain..  Biochemical and biophysical research communications,    (30):   [PMID:1482348]
6. Chan, A M AM and 5 more authors..  (1991)  Identification of a competitive HGF antagonist encoded by an alternative transcript..  Science (New York, N.Y.),    (29):   [PMID:1720571]
7. Rubin, J S JS and 9 more authors..  (1991)  A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor..  Proceedings of the National Academy of Sciences of the United States of America,    (15):   [PMID:1824873]
8. Miyazawa, K K, Kitamura, A A, Naka, D D and Kitamura, N N..  (1991)  An alternatively processed mRNA generated from human hepatocyte growth factor gene..  European journal of biochemistry,    (10):   [PMID:1826653]
9. Weidner, K M KM and 9 more authors..  (1991)  Evidence for the identity of human scatter factor and human hepatocyte growth factor..  Proceedings of the National Academy of Sciences of the United States of America,    (15):   [PMID:1831266]
10. Seki, T T, Hagiya, M M, Shimonishi, M M, Nakamura, T T and Shimizu, S S..  (1991)  Organization of the human hepatocyte growth factor-encoding gene..  Gene,    (30):   [PMID:1831432]
11. Miyazawa, K K, Kitamura, A A and Kitamura, N N..  (1991)  Structural organization and the transcription initiation site of the human hepatocyte growth factor gene..  Biochemistry,    (24):   [PMID:1832556]
12. Seki, T T and 8 more authors..  (1990)  Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte..  Biochemical and biophysical research communications,    (15):   [PMID:2145836]
13. Miyazawa, K K and 9 more authors..  (1989)  Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor..  Biochemical and biophysical research communications,    (15):   [PMID:2528952]
14. Nakamura, T T and 7 more authors..  (1989)  Molecular cloning and expression of human hepatocyte growth factor..  Nature,    (23):   [PMID:2531289]
15. Cioce, V V and 7 more authors..  (1996)  Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity..  The Journal of biological chemistry,    (31):   [PMID:8662798]
16. Zhou, H H and 7 more authors..  (1998)  The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site..  Structure (London, England : 1993),    (15):   [PMID:9493272]
17. Ultsch, M M, Lokker, N A NA, Godowski, P J PJ and de Vos, A M AM..  (1998)  Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution..  Structure (London, England : 1993),    (15):   [PMID:9817840]
18. Stamos, Jennifer J, Lazarus, Robert A RA, Yao, Xiaoyi X, Kirchhofer, Daniel D and Wiesmann, Christian C..  (2004)  Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor..  The EMBO journal,    (16):   [PMID:15167892]
19. Schultz, Julie M JM and 22 more authors..  (2009)  Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39..  American journal of human genetics,      [PMID:19576567]
20. Tolbert, W David WD, Daugherty-Holtrop, Jennifer J, Gherardi, Ermanno E, Vande Woude, George G and Xu, H Eric HE..  (2010)  Structural basis for agonism and antagonism of hepatocyte growth factor..  Proceedings of the National Academy of Sciences of the United States of America,    (27):   [PMID:20624990]
21. Tanaka, Kaoru K and 14 more authors..  (2012)  SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer..  PloS one,      [PMID:22242148]
22. Yoshiyama, Y Y and 9 more authors..  (1991)  Identification of the N-terminal residue of the heavy chain of both native and recombinant human hepatocyte growth factor..  Biochemical and biophysical research communications,    (15):   [PMID:1826837]

Solution Calculators